Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Medartis Holding AG ( (CH:MED) ).
Medartis Holding AG has acquired the remaining 53% of shares in KeriMedical, a company specializing in hand and wrist surgery implants, for CHF 99 million. This acquisition, following the FDA approval of KeriMedical’s TOUCH thumb prosthesis, strengthens Medartis’ position in joint replacement and expands its network of surgeons, with an immediate positive impact on sales growth and EBITDA margin. KeriMedical will continue as an independent brand within Medartis, retaining its development and marketing teams, while co-founders Dougal Bendjaballah and Bernard Prandi remain on the board. The acquisition enhances Medartis’ competencies in hand and wrist surgery, aligning with its strategic goals and expanding its market reach, particularly in Europe, the US, and Australia.
The most recent analyst rating on (CH:MED) stock is a Buy with a CHF86.00 price target. To see the full list of analyst forecasts on Medartis Holding AG stock, see the CH:MED Stock Forecast page.
More about Medartis Holding AG
Medartis, founded in 1997 and based in Basel, Switzerland, is a leading manufacturer and supplier of medical devices for surgical fixation of bone fractures in the upper and lower extremities and the cranio-maxillofacial area. The company employs around 950 people across 13 locations and offers its products in over 50 countries, focusing on innovative titanium implants and instruments.
Average Trading Volume: 3,773
Current Market Cap: CHF1.06B
Find detailed analytics on MED stock on TipRanks’ Stock Analysis page.